KDR and neoplasm: For example, the NRP1-specific small-molecule inhibitors EG00229 and ATWLPPR have been demonstrated to inhibit NRP1-VEGFR-2 signaling, and impair both tumor angiogenesis and tumor growth in vivo (28–30).